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The Fast Dose Calculator (FDC), a track repeating algorithm Monte Carlo method was initially
developed for proton therapy. The validation for proton therapy has been demonstrated in a previous
work. This method can be expanded to ion applications. Our purpose of this paper is to validate
the FDC for carbon therapy. We compare the 3D dose distributions and dose-volume-histograms
(DVH) for carbon calculated by FDC with a full Monte Carlo method, GEANT 4. 19 patients in
total will be discussed, including 3 patients of prostate, 5 of brain, 3 of head and neck, 4 of lung
and 4 of spine. We use gamma-index technique to analyse dose distributions and we do dosimetric
analysis for DVH, a more direct and informative quantity for planning system assessment. The FDC
calculations of both quantities agree with GEANT4. The gamma-index passing rates of all patients
discussed in this paper are above 90% with the criterion 1%/1 mm, above 98% with the criterion
2%/2 mm and over 99.9% with the criterion 3%/3 mm. The Root Mean Square (RMS) of percent
difference of dosimetric indices D02, D05, D50, D95 and D98 are 0.75%, 0.70%, 0.79%, 0.83% and
0.76%. And all the difference are allowed for clinical use.
PACS numbers: 34.80.Lx, 52.20.Fs
I. INTRODUCTION
Particle therapy (Wilson 1946, Amaldi 2005) is considered to have a greater potential to spare healthy tissue than
traditional photon-therapy. It can deliver dose to deep-seated or radioresistant tumors and cause less toxicity to the
healthy tissue around the tumor (Castro et al 2004, Schulz-Ertner et al 2007, Ohno 2013, Poludniowski et al 2015 ).
Thus in the last few years the number of particle therapy facilities has significantly increased (PTCOG website), in
spite of their cost and technological challenges (Newhauser et al 2015). Compared with proton therapy, carbon therapy
produces narrower lateral penumbra, which allows to minimize damage healthy tissue in the proximity the tumor.
Moreover, carbon ions have higher relative biological effectiveness (RBE) than protons (Kraft 2000). This feature
causes more DNA double strand breaks and lead to more non-repairable damage to tumor cells. Even though the
cost of carbon therapy is 2-3 times more than proton therapy, these avantages has boosted its clinical use. Moreover,
good clinical results with carbon therapy have been reported (Schulz-Ertner et al 2004, Tsujii et al 2004).
An essential component of any particle therapy treatment planning system is the dose calculation engine. Tradi-
tionally dose calculations was carried out with Pencil Beam Algorithms (PBS) (Petti 1992, Russell et al 1995, Hong
et al 1996, Deasy 1998, Schneider et al 1998, Schaffner et al 1999, Szymanowski and Oelfke 2002, Taylor et al 2017),
due to their calculation speed. However, it has been shown that Monte Carlo algorithms provide higher accuracy,
especially in areas with large homogeneities (Taylor et al 2017). Traditional Monte Carlo code require calculations
times orders of magnitude larger than PBS algorithms. However, in the last few years a variety of faster Monte Carlos
have been developed (Yepes et al 2009a , b, Dallas MC, Mayo MC, whatever else we can found). Among them, the
only fast Monte Carlo for ion therapy is (Mayo).
Among the fast Monte Carlos, the Fast Dose Calcuator (FDC), a track-repeating Monte Carlo algorithm for
protons was developed by Yepes et al. (Yepes et al 2009a , b), which can increase the calculation speed with respect
to traditional MC by few orders of magnitude. FDC was validated versus full Monte Carlo, GEANT4, for proton
therapy in (Yepes et al 2016) In this work, we report in the extension of FDC to ion therapy and its validation.
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2II. METHODS
III. FDC EXTENSION TO IONS
A stand-alone code, referred to as GEANT4, based on GEANT4 version 10.1.0 (Agostinelli et al 2003, Allison et
al 2006), with the physics list FTF BERT was used for two purposes. Firstly it was utilized to generate the database
of trajectories of carbon ions, C12, in water that was used as an input for FDC. Secondly it was employed to generate
the reference dose distributions for treatment plans for validation.
The database of C12 trajectories in water was generated by simulating 10K carbon ions with an energy of 5200
MeV impinging on a water phantom with the dimension of 510x510x2500 mm3. For each impinging carbon, all the
particles (ions, protons, neutrons, electrons, and gammas) produced from it were stored. In addition, all the steps of
the original particle and of all its daughters were recorded in the database, along with the energy loss, the length,
and direction for each step.
In addition to the trajectory database, parameters to scale the step length for different particles and materials were
calculated and stored in a parameter repository. Similarly to the proton case, we considered a list of 49 biological
and other materials commonly encountered in radiation therapy (lucite, brass, etc). For each material and a charged
particle (ions, protons, and electrons), a table of the Relative Stopping Power (RSP) was stored as a function of
particle kinetic energy in 1 MeV steps. RSP is defined as the stopping power of the material relative to water. The
stopping power was obtained from the method ComputerTotalDEDX from G4EmCalculator for each particle, material
and particle energy.
As for protons (Yepes et al 2016), the particle scaling parameters for scattering angles were obtained by taking
the ratio of the scattering angle in the material relative to water. However, this was implemented as function of
particle energy in 1 MeV steps, while in previous versions of the algorithm ratios were averaged over particle energies.
Scattering angles of particles through a uniform slab of materials of thickness 0.02 g/cm2 were calculated with the
Moliere approximation, as implemented by Lynch and Dahl (1991).
The basic track-repeating principle in FDC remains as in the proton case (Yepes 2009 a, 2009 b). However, the
algorithm was updated to handle ions by utilizing the extended parameter repository with the length and angle scaling
parameters for ions produced in carbon collisions, as explained in the previous section.
IV. PATIENT COHORT
We selected 19 patients from different clinical sites treated at the University of Texas MD Anderson Cancer Center
(MDACC) with Intensity Modulated Proton Therapy (IMPT). The five clinical sites include prostate, brain, head
& neck, lung and spine. For each type, 2 to 5 patients were selected for the study in this paper. The retrospective
planning or dose calculations studies are conducted within purview of a generic protocol approved by an MD Anderson
Internal Review Board.
Since we did not have clinical ion plans available to us, we started with clinically used proton plans, and converted
them into carbon treatment plans. Such conversion was achieved by replacing for each energy layer the proton phase-
space files describing the proton beam with carbon phase-space files, where protons of a given range were replaced
with carbons ions with the same range. Obviously, the dose distributions for the proton and carbon plans are not
exactly the same, because of the different properties of protons and carbon ions. For example, carbon Bragg peaks are
sharper than those for protons, and they have a forward tail due to carbon fragmentation. In spite, of such differences,
the resulting plans are meaningful for our comparison between FDC and GEANT4.
The target volume, prescribed dose, total voxel numbers, voxel size and maximum and minimum energies used in
making plan are presented in Table I.
V. FDC-GEANT4 COMPARISONS
Like in previous studies (Yepes et al 2016), we validate FDC by comparing its dose distributions to those obtained
with GEANT4, a full-fledged Monte Carlo validated against measurements and widely utilized in the hadron therapy
research. Each selected treatment plan is processed with FDC and GEANT4. Both methods are provided with the
Radiation Therapy plan, the CT images and the structure in DICOM format from the clinical treatment planning
system.
In Table II, we also give the statistical uncertainty of each voxel for Geant4 and FDC, which are shown on the 3rd
and 4th column, respectively. The statistical uncertainty is related to the target volumn and number of histories used
3Type Index
Target Volumn
(cm3)
Prescr. Dose
(Gy)
Voxel #
Voxel size
(mm3)
Min Energy
(MeV/n)
Max Energy
(MeV/n)
Prostate 1 21 65 17,796,597 1.95×1.95×1.0 264 361.26
2 31 22.0 21,294,338 1.95×1.95×1.0 267.7 381.9
3 18 38 11,408,683 1.95×1.95×1.25 303 375.5
Brain 1 39 54 12,424,230 1.56×1.56×1.25 137 270.5
2 63 54 11,195,197 1.56×1.56×1.25 135 294.5
3 11 55.4 11,967,150 1.95×1.95×1.25 173 250.5
4 24 50.0 9,564,310 1.95×1.95×1.25 169 278.5
5 63 30.6 9,026,964 1.95×1.95×1.25 135 247
H & N 1 24 70.0 6,482,515 1.95×1.95×2.5 270.5 346.5
2 7 66.0 18,624,294 1.95×1.95×1.0 182.5 387.5
3 14 66.0 22,667,190 1.95×1.95×1.25 219.5 286.5
Lung 1 36 70.0 6,401,252 1.95×1.95×2.5 158 298.5
2 33 66.0 10,125,024 1.95×1.95×2.5 181 250.5
3 117 63 5,101,360 2.07×2.07×2.5 204 377
4 125 66 4,270,560 2.34×2.34×2.5 274.5 387.5
spine 1 138 9.0 23,230,350 1.95×1.95×2.0 237 316.5
2 48 45.5 6,794,229 1.95×1.95×2.5 209.5 332.5
3 333 70 10,505,404 1.95×1.95×2.5 135 298
4 36 50 11,393,369 1.95×1.95×2.5 215.5 312.5
TABLE I: Calculation details for all patients, which include target volume, prescribed dose, total number of voxel and minimum
and maximum energies
Type Index GEANT 4 σ FDC σ P11 (%) P22 (%) P33 (%) D02 (%) D05 (%) D50 (%) D95 (%) D98 (%)
Prostate 1 0.396 0.376 96.81 99.82 99.99 0.83 0.66 0.51 0.72 0.73
2 0.425 0.416 95.82 99.64 99.98 0.91 0.92 0.95 1 1.02
3 0.378 0.307 95.80 99.61 99.97 1.44 1.45 1.69 1.58 1.42
Brain 1 0.320 0.171 99.70 100. 100. - 0.52 -0.53 0 0.67 0.79
2 0.356 0.191 99.67 100. 100. -0.32 -0.32 0 0.36 0.37
3 0.314 0.181 99.92 100. 100. -0.10 -0.20 0.11 0.23 0.23
4 0.171 0.105 99.95 100. 100. 0.22 0.22 0.12 0.38 0.13
5 0.417 0.236 99.2 99.98 100. -0.30 - 0.33 0.59 0 0
H & N 1 0.201 0.112 98.71 99.7 100. 0.85 0.77 0.61 0.66 0.33
2 0.456 0.334 96.56 99.93 100. 0.5 0.59 1.19 1.38 1.01
3 0.423 0.181 99.35 99.99 100. 0.58 0.68 0.46 0.91 -0.22
Lung 1 0.335 0.175 99.26 98.99 100. -0.41 -0.41 -0.09 0.19 0.29
2 0.273 0.294 95.22 99.67 99.99 1.5 0.86 1.33 1.38 1.41
3 0.393 0.198 97.63 99.92 100. 0.85 0.67 0.61 0.66 0.33
4 0.364 0.176 90.28 99.60 99.98 1.23 1.25 1.42 1.43 1.64
spine 1 0.257 0.269 98.42 99.97 100. 0 0 0.73 0 0
2 0.189 0.141 99.10 99.98 100. 0.51 0.52 0.57 0.16 0.17
3 0.426 0.207 98.46 99.97 100. -0.42 -0.34 0.09 0.09 0.1
4 0.290 0.136 99.93 100. 100. -0.50 -0.75 -0.67 -0.91 -0.78
RMS 0.35 0.24 97.91 99.83 100. 0.75 0.70 0.79 0.83 0.76
TABLE II: Summary of gamma-index passing rates and difference between the GEANT4 and FDC dosimetric indices for the
target volume for all patients. Three different criteria are used for gamma-index calculation: 1%/1mm (P11), 2%/2mm (P22 and
3%/3mm (P33). D02, D05, D50, D95 and D98 are the maximum dose covering 2%, 5%, 50%, 95% and 98% of the target.Values
in the last line are root mean square of all patients.
in the calculation. Higher number of histories will bring down the statistical uncertainty. And larger target volumn
needs more number of histories to get lower statistical uncertainty.
The statistical uncertainty σ can be calculated in the following steps:
D =
1
N
N∑
i=1
Di
4,
σ =
√√√√ 1
N
N∑
i=1
(Di −D)
where i is the index of the each voxel, Di is the dose deposit for each particle in every step in a particular voxel, and
D is the mean dose deposit. Note that for those voxels with dose below 10% of the maximum dose are ignored. It
requires extra storage space. So it is only kept for voxel energy, then transformed into statistical uncertainty in Dose.
The number of histories is 30 M for each beam when performing FDC calculation. Because the computing time for
GEANT4 is usually about 7000 to 18000 times more than FDC, we did not use the same number histories as FDC.
The number of histories selected for GEANT4 is to make sure the statistical uncertainty blow 0.4. For all patients
discussed in this paper, the number of histories is between 10M to 65M for each beam. As can be noted, by comparing
the 6th column with the 5th one, most of the statistical errors for FDC are lower than that for GEANT4 because the
number of histories used in FDC is higher than that in Geant4.
We compare the Geant4 and FDC 3D dose distributions by calculating the gamma-index (Low D A, Harms W B,
Mutic S and Purdy J A 1998 A technique for the quantitative evaluation of dose distributions Med. Phys. 25 656),
which considers both the difference in dose value and spatial position. It is calculated for all voxels with a dose larger
than 10% of the maximum dose. We used an algorithm that uses the distance-to-simplex approximation as described
in Ju et al 2008 (Ju et al 2008) with the criteria 1%/1 mm, 2%/2 mm and 3%/3 mm. A passing rate is calculated
defined as the percentage of voxels that are within the tolerance (gamma index smaller than one).
In addition, we calculate Dose Volume Histograms (DVHs) with FDC and GEANT4 and analyze the difference.
DVHs are calculated for structures contoured by physicians. We find that the larger disagreements between FDC
and GEANT4 are found for target volumes (TV). We attribute this behavior to the fact that TV are more sensitive
to statistical fluctuations than DVHs of Organs at Risk (OAR). Therefore we have concentrated our analysis on this
more challenging case of TVs. In order to evaluate the difference in DVHs, we compared D02, D05, D50, D95, and
D98, defined as the the maximum dose covering 2%, 5%, 50%, 95% and 98% of volume of the considered structure
respectively.
VI. RESULTS AND DISCUSSION
A. Dose distribution
The gamma-index analysis is done for all patients with three different criteria, 1 mm/1%, 2 mm/2% and 3 mm/3%.
The passing rates with different criteria for all patients were listed in the 5th, 6th and 7th column of Table II. For
all the patients, their passing rates are over 90.2% for 1 mm/1%, 98.9% for 2 mm/2% and 99.9% for 3 mm/3%. The
RMSs are listed in the last line of Table II, which are 97.91, 99.83 and 100 for different criteria. The high passing
rates demonstrate that the FDC dose distributions agree well with that calculated by GEANT 4. These passing rates
are visualized in Figure 1, from bottom to top of which are 1 mm/1% (P11 black dots), 2 mm/2% (P22, red squares)
and 3 mm/3% (P33, green triangles). Figure 1 showed that the cohort of brain, H&N and spine patients have higher
gamma-index passing rates than other three types.
We select a head & neck patient (Index 1) as an example to show the FDC-dose, GEANT4-dose and their difference
distributions for a specific section in Figure 2. The first plot in this figure is the dose distribution projected in the
transverse plane with z=100 mm calculated by FDC. The one in the middle is the dose projection in the same plane
from GENAT4. The last panel is the dose difference between two methods (FDC - GEANT4). As shown in the first
two plots, the dose distributions simulated by the two methods are similar to each other. Their differnce displayed in
the last panel shows that the maximum dose difference is of the order of 1 Gy, which confirms that the two methods
agree with each other.
The dose distributions in x (lateral), y(anterior-posterior) and z (superior-inferior) projections for all the patients
were also compared for a fast evaluation of the agreement. As an example, Figure 3 displays the x, y and z projections
for the same patient discussed above. The curves of three projections calculated by the two methods coincide.
B. Dose-Volume-Histogram
D02, D05, D50, D95 and D98 for target volumn for all patients are calculated by GEANT4 and FDC. For each index
of DVH, the relative difference between the GEANT4 and FDC values was calculated and listed in columns 8-12 of
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FIG. 1: Gamma-index passing rates for all patients of five different sites studied in this paper. From bottom to top, the
criteria used for Gamma-index calculation are 1 mm/1% (P11, black dots), 2 mm/2% (P22, red squares) and 3mm/3% (P33,
green triangles).
Table II. The RMS of each index for all patients was calculated and listed in the last line of Table II. The difference
in percentage is below 1.5% for D02, 1.45% for D05, 1.69% for D50, 1.58% for D95 and 1.64 for D98. The RMSs of
differences in D02, D05, D50, D95, D98 calculated by two codes are 0.75%, 0.70%, 0.79%, 0.83% and 0.76% respectively,
which confirm that the DVH calculated by two codes agree well with each other. All these values of difference between
GEANT4-DVH and FDC-DVH for target are displayed in Figure 4. The agreement for brain and spine patients is
better than the other three types patients, which is consistent with the comparison of dose distribution.
Figure 5 displays DVHs of the same head & neck patient mentioned above for four selected structures: GTV (black),
Hypothalamus (red), Brain Stem (green) and Frontal Lobe (light blue). The open squares and solid line are for FDC
and GEANT4 calculations, repectively. The comparisons show that the DVHs calculated by the two methods agree
well with each other. Especially, the DVHs for Brain Stem and Frontal Lobe from the two methods are virtually
indistinguishable.
6G
y
10
20
30
40
50
60
70FDC
G
y
10
20
30
40
50
60
70G4
G
y
2.5−
2−
1.5−
1−
0.5−
0
0.5
1
1.5
FDC-G4
FIG. 2: Gamma-index passing rates for all patients of five different sites studied in this paper. From bottom to top, the
criteria used for gamma-index calculation are 1 mm/1% (P11, black dots), 2 mm/2% (P22, red squares) and 3mm/3% (P33,
green triangles).
FIG. 3: Dose distribution projection in the direction superior to inferior (x), left to right (y) and anterior to posterior (z) for
the same patient calculated by FDC (black line) and GEANT4 (red line)).
VII. CONCLUSIONS
In this paper, we used GEANT 4, a widely used full-fledged Monte Carlo code as the standard to verify the accuracy
of the Fast Dose Calculator (FDC) code in carbon patients calculation. We compared dose distributions and dose-
volume-histograms (DVH) calculated by FDC and GEANT4. The gamma-index passing rates with the criterion 2%/2
mm are above 98.5% for all patients, and the passing rates are above 99.9 for all patients if 3%/3 mm is used. For
DVH, the Root Mean Square (RMS) for the difference of five selected slices (D02, D05, D50, D95, D98) calculated by
FDC and GEANT4 are below 0.75%, 0.70%, 0.79%, 0.83% and 0.76% respectively. Therefore, the FDC accuracy
amply satisfies the requirement for clinical use.
7FIG. 4: Difference of five different indices of target volum DVH: D02 D05, D50, D95, and D98. Negative difference means
FDC-DVH is small than GEANT4-DVH.
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